Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 8OTHER 7NIH 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 21Brain Neoplasms 9Neoplasms 7Glioma 6Astrocytoma 4Recurrence 3Solid Tumor 1Sarcoma 1Pancreatic Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Camurati-Engelmann Syndrome 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Temozolomide 3Irinotecan 3tozuleristide 2selpercatinib 2lenvatinib 2gadobenic acid 2avelumab 2Radiation 2Paclitaxel 2Leflunomide 2Immunotherapy 2Gemcitabine 2Everolimus 2Cisplatin 2Carboplatin 2Cancer Vaccines 2Bevacizumab 2Adjuvants, Immunologic 2ridaforolimus 1regorafenib 1prinomastat 1pomalidomide 1perillyl alcohol 1pemigatinib 1pembrolizumab 1pamiparib 1omburtamab I-131 1irinotecan sucrosofate 1interferon gamma-1b 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Central Nervous System Neoplasms × Lomustine × Clear all
NCT07100730 2026-04-16

IPAX BrIGHT

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡